Brain in flames - animal models of psychosis: utility and limitations by Mattei, D. et al.
© 2015 Mattei et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Neuropsychiatric Disease and Treatment 2015:11 1313–1329
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1313
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S65564
Brain in flames – animal models of psychosis: 
utility and limitations
Daniele Mattei1
Regina Schweibold1,2
Susanne A Wolf1
1Department of Cellular 
Neuroscience, Max-Delbrueck-
Center for Molecular Medicine, 
Berlin, Germany; 2Department 
of Neurosurgery, Helios Clinics, 
Berlin, Germany
Abstract: The neurodevelopmental hypothesis of schizophrenia posits that schizophrenia is 
a psychopathological condition resulting from aberrations in neurodevelopmental processes 
caused by a combination of environmental and genetic factors which proceed long before the 
onset of clinical symptoms. Many studies discuss an immunological component in the onset and 
progression of schizophrenia. We here review studies utilizing animal models of schizophrenia 
with manipulations of genetic, pharmacologic, and immunological origin. We focus on the 
immunological component to bridge the studies in terms of evaluation and treatment options 
of negative, positive, and cognitive symptoms. Throughout the review we link certain aspects 
of each model to the situation in human schizophrenic patients. In conclusion we suggest a 
combination of existing models to better represent the human situation. Moreover, we emphasize 
that animal models represent defined single or multiple symptoms or hallmarks of a given 
disease.
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Introduction
Over the past 20 years, an increasing amount of evidence supports the involvement of 
inflammatory processes in the pathophysiology, and more recently in the etiology of 
schizophrenia. High levels of proinflammatory cytokines are found in the blood and 
in the cerebrospinal fluid of schizophrenia patients.1,2 Current treatments with classi-
cal or atypical antipsychotics have significantly improved the life quality of affected 
individuals; however, these medications have often severe side effects, especially when 
taken over a long period of time.3 Moreover, existing antipsychotic drugs, including 
clozapine, treat only a subset of the symptoms. Existing drugs have little (or no) efficacy 
against the cognitive and negative symptoms that are responsible for much disability.4–6 
The second-generation antipsychotic drugs have far less tendency than the older drugs 
to cause serious motor system side effects. But the newer drugs carry their own burden 
of serious side effects, such as significant weight gain and elevated levels of glucose 
and lipids.7–9 In clinical trials, minocycline, an anti-inflammatory antibiotic has been 
used with positive outcomes on the negative and cognitive symptoms.10–12
A growing body of literature also supports an increased appreciation for the 
integrated role of microglia in psychiatric disorders research. Microglia cells are the 
resident immune competent cells and phagocytes of the brain. Recently, microglia 
have been identified as potential pathological key player in schizophrenia.13 Evaluat-
ing postmortem tissue, an increase in reactive microglia density has been reported in 
distinct subtypes of schizophrenia and different brain regions.14 Using a ligand for the 
peripheral benzodiazepine receptor and PET (positron emission tomography) scans, a 
state of neuro inflammation in vivo in schizophrenic patients have been confirmed.15,16 
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Interestingly, microglial activation has also been found in 
animal models such as the maternal immune activation (MIA) 
that mimics a plethora of schizophrenia-like symptoms and 
hallmarks. The use of the antibiotic minocycline in animal 
models of schizophrenia proved the efficacy of treatments 
targeting microglia, the primary source of reactive oxygen 
species and proinflammatory cytokines in the brain, on 
schizophrenia-like manifestations.17–20 Minocycline is also 
able to decrease glutamate release through the interaction 
with voltage-dependent Ca2+ and Na+ channels, and this 
mode of action may also participate in the outcome of such 
a treatment in this pathology.21
Microglia orchestrates neuroinflammation and thus might 
become a new target of anti-inflammatory treatments. We 
here review present animal models in connection to either 
microglial activation and/or anti-inflammatory treatment 
outcome to see whether inflammatory processes are bridging 
the heterogeneous pool of animal models of schizophrenia. 
In addition, identifying a common inflammatory pattern 
would rationalize the use of anti-inflammatory drugs as an 
adjunctive therapeutic option.
When it comes to the development of animal models for a 
given neuropsychiatric condition, three main validity domains 
are usually screened to assess the strength of the model in 
reproducing a given human condition: construct validity, that 
is how the model was developed in terms of fidelity toward the 
given natural causes of the disease in humans; face validity, 
which describes a model’s reliability in terms of symptom 
array and biological changes pertinent to the disease being 
studied; predictive validity, how well the model responds 
to present medication used to treat the given disorder in 
comparison to how human patient responds and therein how 
valid the model is for testing of new compounds and biologi-
cal targets for future research.22 The models described in this 
review will be addressed to as “models of schizophrenia”. 
However, schizophrenia is a complex human disorder with 
a yet unclear etiology and pathophysiology; it is therefore 
not reproducible in animals. The models used up to date all 
express several of the known neurochemical and behavioral 
abnormalities related to the human clinical picture of schizo-
phrenia. Every time we refer to “models of schizophrenia” 
here, we actually address only a distinct manifestation of 
symptoms, hallmarks, and traits of the human disease, which 
will be discussed in detail for each model.
Genetic models
Schizophrenia has been linked to many different gene 
variants and mutations. Nevertheless, it is more probable 
that susceptibility genes together with environmental 
factors influencing the epigenome bring about the neu-
rodevelopmental process leading to a schizophrenic 
phenotype.23–25 In order to study the effect of genes in 
the pathophysiology of schizophrenia, many different 
transgenic mouse models have been developed. Because 
of the large number of schizophrenia-related transgenic 
mice, we refer here to the works of Miyamoto and Nitta26 
and van den Buuse,27 which thoroughly reviewed the vast 
array of genetic models in this regard. We decided to dis-
cuss briefly only one of the most studied group of genetic 
mouse models of schizophrenia, the DISC1 (disrupted in 
schizophrenia-1) transgenic mice. The dominant-negative 
DISC1 mouse has a forebrain-specific expression of 
dominant-negative truncated DISC1 under the promoter 
for calcium/calmodulin-dependent kinase II in C57BL/6 
mice, which shows the typical cellular and morphological 
changes observed in patients, such as decreased parvalbu-
min (PV)-expressing interneurons and enlarged ventricles. 
As reviewed by van den Buuse,27 though, not all DISC1 
transgenes do show a clear-cut schizophrenic phenotype in 
terms of sensorimotor deficits, hyperlocomotion, and other 
symptoms. This reflects the fact that genetic changes in one 
gene are probably not enough to reproduce the complexity 
of this disease, and the outcome of any DISC1 transgene 
may depend on the applied truncation or deletion in the 
exons of the mouse Disc1 gene.27,28 Changes in microglia 
cell phenotype and function in this mouse would be of par-
ticular interest in light of the fact that DISC1 is expressed 
in microglia cells (and also the other glia cells, astrocytes, 
and oligodendrocytes) in both humans and rats.29 In sum-
mary, the discovery of susceptibility genes has helped 
scientists to understand which biological pathways are 
possibly perturbed in schizophrenic endophenotypes. It is 
therefore conceivable that the same pathways or genes can 
be altered also in the absence of genetic mutations, eg, by 
environmental challenges against which cells respond via 
epigenetic mechanisms to adapt to changed conditions.23 
One example is the changes in reelin expression observed 
in schizophrenic patients, which prompted scientists to 
develop reelin KO-mice as a model of schizophrenia, while 
schizophrenic patients do not present a full deletion of the 
reelin gene.30 On the other hand, the adult offspring of 
PolyI:C-challenged pregnant dams (discussed later in the 
review) presents a naturally diminished reelin expression 
following MIA, a known environmental risk factor for 
developing schizophrenia.31,32 In the same line, it appears 
that prenatal MIA is able to also alter the expression of 
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DISC1 in the hippocampus of adult offspring.33 A final 
remark on genetic models is the lack of studies testing 
antipsychotic treatment on the behavioral features dis-
played by this pool of models. Future research should 
aim at validating these models for predictive validity so 
as to assess the effect of antipsychotics on the genetic 
component of this disease. Table 1 summarizes the major 
behavioral deficits found in the DISC1 mouse for a better 
overview.
Pharmacological models
Pharmacological models are a valuable tool through 
which specific underlying causes of schizophrenia can 
be reproduced. One example is the induction of gluta-
matergic hypoactivity observed in schizophrenic patients 
by injecting NMDA receptor antagonists into adult mice 
or rats.34–36 The most widely used and explored NMDA 
receptor antagonists are phencyclidine (PCP), ketamine, 
and dizocilpine (MK-801). The use of these compounds to 
reproduce schizophrenic-like symptoms such as psychosis 
came from the observation that humans administered with 
or without abusing these compounds develop features of a 
wide array of symptoms matching many of the positive, nega-
tive, and cognitive symptoms of schizophrenia. Moreover, 
schizophrenic patients administered with NMDA receptor 
antagonists experience a worsening of symptoms.37,38 The 
strength of this model is the simplicity in producing it and the 
possibility to quickly test new pharmacological interventions. 
The downside of the model is that it lacks the neurodevel-
opmental component that is thought to be the basis for the 
structural and cytoarchitectural abnormalities that result in 
the symptomatology of schizophrenia.30 On the cognitive 
symptoms side, ketamine administration has been reported 
to induce working memory deficits in the Y-maze, but no 
impairments were observed in the novel object exploration 
test.39,40 On the negative symptoms side, ketamine increases 
immobility in the forced swim test, decreases social interac-
tion, and increases anxiety-like behaviors. Signs of positive 
symptoms include deficits in PPI (prepulse inhibition), PCP/
MK-801-induced hyperlocomotion, and disrupted latent 
inhibition (LI). Comparable to the human clinical situation, 
atypical antipsychotics are more effective than the typical 
ones in treating the negative symptoms in this model. Halo-
peridol (a typical antipsychotic) seems to have no effect 
on the negative and cognitive symptom manifestations in 
this model, but it is efficacious against the positive ones, 
while clozapine (an atypical antipsychotic) has been found 
to revert both symptomatologies, which means that this 
model has a good predictive validity to test the efficacy of 
novel compounds in different symptom domains pertinent 
to schizophrenia pathology.39–43 PCP induced a huge array 
of cognitive manifestations, namely, deficits in novel object 
recognition, attentional set shifting, and T-maze delayed 
alternation and reversal learning. Moreover, it disrupted 
working and short-term memory. As for the positive-like 
symptoms, hyperlocomotion, disrupted PPI and LI have been 
reported along with negative symptoms such as impaired 
social behavior and enhanced immobility in the forced swim 
test. Similar to the ketamine model, haloperidol is able to 
reverse positive but not cognitive or negative symptoms, 
whereas clozapine showed positive effects on most behav-
ioral abnormalities.44–52 The same cognitive, negative, and 
positive symptoms manifestations have also been found 
upon administration of MK-801, with very similar out-
comes of anti psychotic treatment.53–58 In summary, although 
NMDA antagonism does not represent the perfect construct 
validity as a model, it shows a very good face validity in 
terms of schizophrenia-related behavioral abnormalities and 
an appreciable predictive validity according to the studies 
testing present antipsychotics.
NMDA antagonism causes acute and reversible miss- 
wiring of brain areas involved in schizophrenia, leading to 
schizophrenia endophenotypes and also indirectly to dopamin-
ergic derangements.35,59 Nevertheless, the fact that minocy-
cline pretreatment prevents the induction of positive, negative, 
and cognitive symptoms associated with NMDA antagonism 
implies that some form of inflammation may also be involved 
in this model.40 It has been reported that NMDA antagonism 
can, depending on the dose and number of administrations, 
damage neurons and lead to apoptosis and inflammatory 
responses.39,45,60 This in turn may lead to microglial activation 
and cytokine production in a brain region specific fashion. 
In fact, Zhu et al44 reported microglial activation following 
chronic PCP administration. In this regard, minocycline can 
be beneficial in two different ways: one is through minocy-
cline’s neuroprotective and antiapoptotic action,61,62 and the 
other is the prevention of microglial activation.63,64 A study 
reported necrotic cortical neurons even with a dose of 1 mg/kg 
of MK-801, with intracellular vacuolization associated with 
reactive microglia. At higher doses (5 and 10 mg/kg), this 
response was even more evident.65 Monte et al40 reported 
that minocycline treatment was efficient in both preventing 
and treating the ketamine-induced cognitive, negative, and 
positive schizophrenia endophenotypes. Zhang et al66 showed 
that minocycline treatment can attenuate MK-801-induced 
hyperlocomotion and PPI deficits, showing here too that 
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treatment after the administration of NMDA antagonists is 
effective. Finally, Fujita et al48 found that minocycline treat-
ment successfully improved the cognitive deficits induced 
by chronic PCP administration. It is believed that oxidative 
stress is also part of the pathophysiology of schizophrenia.67,68 
It is therefore inferable that minocycline acts on other 
aspects besides the anti-inflammatory action, considering it 
has scavenger and anti-apoptotic properties and modulating 
glutamatergic neurotransmission. Table 1 summarizes the 
major behavioral deficits found in this group of models and 
the outcome of the various treatments.
Lesion and developmental models
While pharmacological models of schizophrenia were cre-
ated based on early observations of the neurochemical 
changes in brains of schizophrenic patients, subsequent 
models focused more on the theory of a neurodevelopmental 
hypothesis of schizophrenia. One of the first attempts to 
reproduce a possible developmental perturbation was the 
neonatal ventral hippocampal lesion (nVHL) model in rats. 
In this model, an excitotoxic lesion is provoked in the ventral 
hippocampus (VH) on postnatal day 7 (P7) by local and 
bilateral administration of either ibotenic acid (permanent 
lesion) or tetrodotoxin (temporary inactivation of the 
VH).69,70 The rats show features of positive, negative, and 
cognitive correlates of symptoms observed in schizophrenia 
as they reach late puberty. This is more alike the human 
clinical situation and hypothesis of a neurodevelopmental 
course of the disease than the pharmacological induced 
models.71 In the adult brain, the VH is functionally connected 
to the striatum, nucleus accumbens (NAc), prefrontal cortex 
(PFC), and amygdala. The nVHL will result in an aberrant 
development of connections between the VH and these areas, 
leading to an aberrant development of the PFC. The latter 
region will then result to be disinhibited in the adult lesioned 
rats.72–74 This is believed to be the net result of an absent 
maturation of dopamine (DA) receptor 2 (D
2
 receptor)-
mediated control of fast-spiking interneurons  within this 
structure, which should occur by the end of puberty. The 
connections between the aforementioned areas are not fully 
functional until early adulthood, and it is believed that other 
areas take over until then, so that any developmental miscon-
nection within these circuits will not appear symptomatically 
until these areas, in early adulthood, are functionally imple-
mented in the circuitry.75,76 Alterations in the dopaminergic 
system have been reported in the lesion model, mainly in 
the form of increased DA levels in hippocampus and an 
increase in its metabolite dihydroxy phenylacetic acid in the 
mPFC (medial prefrontal cortex).77 Flores et al78,79 further 
reported increased binding of DA receptor 3 (D
3
) in limbic 
subregions and also increased binding of D
1
 and D
2
 receptors 
in the striatum, suggestive of dopaminergic hyperactivity in 
this limbic region. Furthermore, decreased binding of glu-
tamate was found along with alterations of the dopaminergic 
and glutamatergic neurotransmission in adult rats with post-
natal ibotenic acid hippocampal lesion.80 Finally, the GABA 
(γ-aminobutyric acid)ergic interneuron system has also been 
found to be altered.81,82 Changes in the cortical GABAergic 
interneuron system have been proposed to play a pivotal role 
in many aspects of the symptomatology of schizophrenia, 
since aberrations in this system seem to contribute to the 
cortical miss-wiring and disinhibition observed in these 
patients; hence, these findings highlight an important similar-
ity of this model to the clinical piture.30,83 The nVHL model 
also displays cytoarchitectural abnormalities congruent with 
the findings in human studies on schizophrenic patients.30 
Flores et al84 reported decreased spine density and dendritic 
length in PFC and NAc medium spiny neurons, in line with 
the cytoarchitectural abnormalities known in schizophrenia 
pathology. Also, decreased spinogenesis and neuronal atro-
phy have been found in the NAc, PFC, and basolateral 
amygdala of the nVHL rats.85 As the lesioned animals reach 
early adulthood, they show features of negative symptoms 
in the form of social withdrawal in the sociability test and 
enhanced immobility in the forced swimming test when 
administered with PCP.86 As signs of positive symptoms, 
they show amphetamine- and PCP-induced hyperactivity, 
deficits in sensory and sensorimotor gating, increased aggres-
sive behavior and higher risk-taking behavior in the elevated 
plus maze, and also disrupted LI.85,87–90 The lesioned animals 
have been found to have deficits in working and spatial 
memory as measured in the Morris’s water maze and 
T-maze.91–93 The lesion model is mainly applied in rats, and 
recently, Naert et al87 carried out a large behavioral screening 
of this model in C57B1/6J mice. They showed that lesioned 
mice present with higher spontaneous and amphetamine-
induced activity and higher risk-taking behavior in the ele-
vated plus maze. Further, they found deficits in working 
memory assessed by means of Y-maze (spontaneous alterna-
tion) and t-test (online storage of information). Working 
memory in these tasks is dependent on proper PFC function, 
and these deficits can be related to the known aberrant PFC 
function in nVHL rats. Nevertheless, the mouse model of 
nVHL did not display deficits in spatial memory assessed 
with the Morris’s water maze, and also the social behavior 
was intact. Furthermore, these mice had an intact sensorimotor 
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gating and LI. These results shows that the mouse model 
differs from the rat model which seem to congregate more 
symptom domains as compared to the mouse model.87 One 
major advantage of the nVHL mouse model conceived by 
Naert et al87 is that it can be combined with genetic mouse 
models of schizophrenia endophenotypes in order to encom-
pass more etiological factors. The lesion model has, in 
general, good face validity, encompassing many symptom 
domains of schizophrenia with a neurodevelopmental com-
ponent and a postpubertal manifestation of symptoms. As 
for the predictive validity, the outcome of antipsychotic 
testing has been quite mixed. So far, clozapine and haloperi-
dol have been shown to be able to reverse drug-induced 
hyperactivity.94 Becker et al90 showed that haloperidol did 
not restore the deficit in social behavior but decreased the 
aggressive behavior, which is more related to the positive 
symptoms of schizophrenia. On the other hand, clozapine 
did not have any effect on the aggressive behavior but 
restored a normal social pattern. This is in contrast with the 
results of another study in which neither clozapine nor ris-
peridone (another atypical antipsychotic) managed to restore 
a normal social interaction.88 Nevertheless, clozapine, ris-
peridone, and olanzapine improve the deficits in sensorimo-
tor gating, while haloperidol has no effect in this positive 
symptom-like measure, which is not what is expected in 
terms of treatment efficacy, considering the human clinical 
picture.95 Levin and Christopher96 showed that clozapine can 
worsen the already impaired learning and memory functions 
in this animal model. The construct validity of this model 
may be questionable, since schizophrenic patients do not 
display a direct and profound lesion in the anterior hip-
pocampus, which is the corresponding VH in rodents.97 
Somehow, this model shares a component with the viral and 
bacterial developmental models of schizophrenia (discussed 
later). The immune response in the mother and consequently 
in the fetal brain may represent the spark of an initial damage 
directed against neurodevelopmental processes involving, 
among other regions, the hippocampus. In this regard, these 
models have one thing in common: microglia activation and 
ongoing inflammatory processes that may be the basis of the 
developmental perturbation leading to the postpubertal 
outbreak of symptoms. In line with the theory implicating 
developmental neuroinflammation in the pathophysiology 
of schizophrenia, Drouin-Ouellet et al98 analyzed in a recent 
study the role of microglia cells in the nVHL. They 
reproduced the postpubertal impairments showed by others 
in this model, including amphetamine-induced hyperlocomo-
tion, deficits in PPI, impaired social interaction, and spatial 
working memory deficits. They could detect microglial 
activation following ibotenic acid injection from early after 
the injection until P35, long after ibotenic acid treatment, 
but not in adulthood (P56); moreover, interleukin-1 beta 
(IL-1β) was upregulated in the hippocampus until P14. 
Interestingly, they observed a selective induction of the 
metabotropic glutamate receptor 5 only in activated micro-
glia, implicating the glutamatergic system in this immune 
response. Finally, they showed that treatment with minocy-
cline 12 hours and 30 minutes prior to ibotenic acid admin-
istration and for 3 days following surgery prevented 
microglial activation, the raise in IL-1β, and the outbreak of 
the aforementioned symptoms. Interestingly, it also pre-
served to a certain extent the VH neuronal loss following 
ibotenic acid injections.98 They basically show that microglial 
activation is largely responsible for the short- and long-term 
consequences of nVHL with ibotenic acid. Two recent stud-
ies confirm these findings, further linking developmental 
neuroinflammation and microglial activation in the develop-
ment of a schizophrenic endophenotype in this model. 
Feleder et al73 combined the lipopolysaccharide (LPS)-in-
duced developmental model (discussed later) with the nVHL 
model by injecting LPS bilaterally in the VH at P6–P7 in 
rats. The rationale behind this model is to have a construct 
that implements a local inflammatory perturbation without 
any severe and destructive lesion. The authors showed that 
this kind of LPS challenge does not lead to changes in hip-
pocampal morphology. Then, they demonstrated an increase 
in IL-1β and IL-2 in the hippocampus, PFC, and NcA, which 
was persistent and detectable also in adulthood.73 Interest-
ingly, the same persistent increase in brain cytokines has 
been found in postmortem tissue from schizophrenic patients, 
suggesting that if any developmental perturbation occurred 
in pre- or perinatal stages of their lives, it may have given 
rise to a persistent increase in proinflammatory mediators.99–101 
In a recent study, Zhu et al102 reproduced this model, dem-
onstrating that nVHL challenge with LPS also leads to nega-
tive and cognitive manifestations in the adult rats which 
show deficits in social interaction and novel object recogni-
tion. Furthermore, they displayed PPI deficits as a sign of 
positive symptoms, but no locomotor hyperactivity. Here 
the authors found a marked increase in microglia density in 
the VH, thalamus, and cortex of the adult rats injected in the 
VH with LPS at P7. These rats were treated with minocycline 
and risperidone either alone or in combination, starting from 
P42 for 14 consecutive days. The authors report that both 
compounds, either alone or in combination, managed to 
rescue all the behavioral abnormalities and also the increase 
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in microglia density in the aforementioned brain areas.102 
This study shows that minocycline is effective in this model 
as a treatment and not only as a pretreatment as demonstrated 
earlier by Feleder et al.73
Both studies demonstrate that a persistent lesion is 
not required to reproduce a valid schizophrenia endo-
phenotype with neonatal perturbation of the VH, as also 
demonstrated by the transient VH inactivation model with 
tetrodotoxin. In conclusion, the latter three studies carried 
out by Drouin-Ouellet et al,98 Feleder et al73 and Zhu et al102 
implicate microglia density and inflammatory processes in 
the developmental course of this animal model, suggesting 
that anti-inflammatory intervention can prevent the outbreak 
of schizophrenia-like symptoms when administered early 
and also when administered in later pubertal stages. Further 
studies may address the questions as to why inflammatory 
processes and microglia cells are activated in regions far 
from the actual site of lesion/LPS injection, and how this 
activation can be so persistent. Table 1 summarizes the major 
behavioral alterations found in this group of models and the 
outcome of the various treatments.
Maternal immune activation models
Prenatal PolyI:C
Epidemiological studies revealed a correlation between certain 
viral and bacterial infections during pregnancy and the develop-
ment of schizophrenia in the offspring.103 This finding was fur-
ther strengthened by more recent serological studies conducted 
on the blood samples collected during pregnancy from mothers 
of children who developed schizophrenia.104,105 Fatemi et al106 
during the early nineties showed that inoculation of human 
influenza virus in pregnant rodent dams caused the offspring 
to develop naturally a schizophrenia endophenotype as they 
reached early adulthood, with changes in various gene expres-
sion profiles in the brain, affecting also schizophrenia-related 
symptoms. The model was further developed using more 
practical means of evoking MIA by avoiding human patho-
gens. Instead of actual viruses, the double-stranded synthetic 
RNA PolyI:C is used nowadays.107 Double-stranded RNA is 
a product of viral replication for most kinds of viruses, and it 
is recognized by toll-like receptor 3 (TLR3) as a viral com-
ponent, thereby evoking an innate antiviral immune response 
that includes the production of proinflammatory cytokines 
such as IL-1β, IL-6, TNF-α, and type I interferons: INF-α 
and INF-β.108 It is believed that the maternal immune response 
interferes with the correct development of the fetal brain in 
sensitive time-windows of pregnancy.109 In rodents, MIA at 
gestational day (G)15 gives rise to a reliable schizophrenia-like 
phenotype in the adult offspring, which will present hallmark 
structural changes found in schizophrenic patients, including 
enlarged ventricles and thinning of the hippocampus, which 
can be blocked by administering atypical antipsychotics dur-
ing the asymptomatic period in adolescence.110–112 Although 
G15 is a commonly used gestational day, MIA at G9 and G17 
also gives rise to schizophrenia endophenotype pathological 
components.113,114 To analyze the exact outcome of prenatal 
PolyI:C on the many different gestational days used is beyond 
the scope of this review; nevertheless in the discussion that 
follows, we will specify the day of MIA when relevant in the 
context of major phenotypical differences. Additionally, the 
last trimester of pregnancy in humans corresponds to P2–P6 in 
rodents, and in this case the animals are injected postnatal and 
the PolyI:C is given once a day for these 5 consecutive days.115 
We decided not to elaborate on the neonatal PolyI:C model 
since it lacks the maternal immune response–fetal interface 
that reproduces the reported risk factor in a biologically more 
congruent way.
The adult offspring of dams challenged with PolyI:C 
(also referred to here as PolyI:C animals) have been found 
to present many histopathological and neurochemical 
hallmarks of schizophrenia in regions implicated in this 
pathology: limbic DA hyperactivity in striatal slices from 
adult brain, along with structural histopathological abnor-
malities in hippocampal CA (cornu ammonis) 1 and CA3 
regions (PolyI:C at G15),116 increased DA turnover and 
decreased D
2
-like receptors binding in the striatum (PolyI:C 
at G12–G17),117 and reduction in reelin- and PV-expressing 
prefrontal neurons.113 This is of particular relevance to the 
PFC disinhibition features also shown by the nVHL model 
and schizophrenic patients thought to be caused, at least in 
part, by a malfunctioning GABAergic system.118 Follow-
ing this line, an increased immunoreactivity for GABA-A 
receptor in the limbic system119 and reduced expression 
of glutamic acid decarboxylase 65 and 67 (GAD65/67) 
isoforms in the PFC and dorsal hippocampus (PolyI:C at 
G17) were reported in this model, which may contribute to 
GABAergic dysfunction. GAD is the rate-limiting enzyme 
in GABA biosynthesis; therefore, we could infer that a 
challenge in late gestation may decrease GABA levels at 
least in PFC and dorsal hippocampus.120 Soumiya et al121 
also reported decreased GAD67 expression in the upper 
cortical layers together with decreased synaptophysin immu-
noreactivity. Winter et al122 screened the content of several 
neurotransmitters in brain regions relevant to schizophrenia 
(PolyI:C at G9). They found that this offspring showed in 
adulthood increased DA levels and its major metabolites in 
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the lateral globus pallidus and PFC and decreased serotonin 
and its metabolite in the hippocampus, NAc, and lateral 
globus pallidus. Nevertheless, central glutamate and GABA 
contents were unchanged. On the other hand, another study 
reported decreased DA, glutamate, and GABA levels in the 
PFC and hippocampus (PolyI:Cat G17).123 These two stud-
ies reveal that different neurotransmitters are differentially 
affected in adult PolyI:C offspring, depending on the timing 
of MIA. Nevertheless, it has to be stressed that dysfunc-
tions in specific neurotransmitter systems may manifest in 
the form of altered receptor or receptor subunit expression 
pattern independently of the gestational day of MIA. For 
instance, a study conducted by Roenker et al124 revealed 
marked glutamatergic hypofunction in the offspring of dams 
challenged at G14, which was manifested through decreased 
NMDA receptor function and elevated extracellular gluta-
mate levels in the PFC. Besides the changes in serotonin and 
glutamate levels, changes in receptor expression for these 
two neurotransmitters have also been shown. Holloway 
et al125 demonstrated that MIA with PolyI:C leads to increased 
expression of the serotonin receptor 5-HT
2A
 and a decrease 
in metabotropic glutamate receptor 2 in the frontal cortex of 
adult offspring. Similarly, Dalton et al126 showed an increase 
in 5-HT
1A
 receptor in the brain of adult PolyI:C animals, 
and the increase was greater if these animals were exposed 
to a cannabinoid during adolescence. These findings are of 
particular relevance since serotonergic dysfunctions have 
been described in this disease and medications acting on the 
serotonergic system are being screened as a possible new 
treatment strategy.127 Another neurotransmitter system found 
to be impaired in both human schizophrenic patients and 
the PolyI:C model is the cholinergic system, with particular 
focus on the nicotinergic receptor system.128–131 Particular 
focus has been put on the α7 nicotinic receptor system, with 
agonists being tested for their efficacy in bettering cognitive 
symptoms of schizophrenia.130–132 Interestingly, Wu et al 
found that following MIA with PolyI:C, there was an increase 
in Chrna7 gene expression, which is the gene encoding for 
the nicotinic acetylcholine receptor α7 subunit in the fetal 
brain.133 This was paralleled by an increase in IL-6 expres-
sion. Furthermore, Chrna7+/- mice were more susceptible to 
MIA and displayed a higher increase in fetal brain IL-6.
In addition to the neurochemical changes, cytoarchitec-
tural abnormalities have also been reported in mPFC and 
dentate gyrus of the hippocampus of PolyI:C animals. These 
abnormalities consisted of decreased complexity and density 
of the dendritic spines (PolyI:C at G9.5).134 Interestingly, 
Soumiya et al121 reported increased presynaptic structure 
density in the upper cortical layers and a decreased number 
of synaptophysin- and GAD67-positive puncta surrounding 
the neuronal bodies in the upper cortical layers, suggestive 
of an imbalance between excitatory and inhibitory syn-
apses. Therefore, prenatal PolyI:C may determine aberrant 
spine-density development in a brain region specific way, 
and dendritic spine pathology is indeed a feature of the 
pathophysiology of schizophrenia.135 Studies conducted with 
human material from schizophrenic patients revealed that 
structural abnormalities are not restricted to dendritic spines 
but are also reported to include white matter abnormali-
ties in the PFCs and in the tracts linking the PFC to limbic 
regions, as reviewed by Najjar and Pearlman.136 Importantly, 
changes in white matter structure correlated with microglial 
activation, changes in GAD65/67 immunoreactivity, and 
increased mRNA for IL-1β and IL-6 in different regions 
of the PFCs. Higher density of neuronal nuclear antigen 
immunoreactive cells was found at the sites of inflammation 
as compared to controls, suggesting that correct develop-
ment and cellular density organization were not properly 
shepherded.136 White matter pathology in schizophrenic 
patients and in PolyI:C mice has also been shown in vivo 
using diffusion tensor imaging, which is a particular kind of 
magnetic resonance imaging often used to analyze white mat-
ter structural integrity.137 Using this method, Alvarado-Alanis 
et al138 and Li et al139 found white matter abnormalities in 
frontostriatal–limbic tracts in the adult PolyI:C mice, reflect-
ing the human abnormalities especially in treatment-naive 
first-episode patients.
Finally, it has been shown that maternal PolyI:C chal-
lenge at G15 impairs neuronal synchrony between the mPFC 
and the hippocampus, and this is a major basis for thought 
disorder and for deficits in PPI.140,141
The adult offspring of PolyI:C-challenged dams pres-
ents with correlates of phenomena pertaining to the posi-
tive, negative, and cognitive symptoms of schizophrenia. 
As signs of positive symptoms, PolyI:C mice display 
psychostimulant-induced hyperlocomotion, deficits in PPI, 
and LI.116,117 Concerning the negative symptoms, they have 
been shown to have deficits in social behavior, decreased 
sucrose preference (anhedonia), and also increased behav-
ioral despair in the forced swimming test.123,142,143 Zhang and 
van Praag144 found, moreover, increased immobility in the 
tail suspension test. The offspring of Poly:IC mice show 
compromised working memory and also intentional set 
shifting deficits along with spatial memory deficits in the 
Morris’s water maze and object-in-place recognition memory 
deficits.120,145–147 Furthermore, impairments in hippocampal 
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dependent behavioral tests along with decreased hippocampal 
neurogenesis have also been reported.144 Chronic clozapine 
treatment has been shown to revert impairments in working 
memory.148 Zuckerman et al116 found that both clozapine 
and haloperidol could revert the deficits in LI. Moreover, as 
reviewed by Dickerson and Bilkey,140 clozapine treatment 
could efficiently restore the deficits in PPI and the aberrant 
neural synchrony between the mPFC and the hippocampus. 
So far, no study has been carried out to test the present 
antipsychotic treatment on the negative symptoms part 
in this MIA model. Behavioral outcomes with PolyI:C pre-
natal exposure seem to be highly dependent on the dam’s 
individual immune response. Missault et al149 discovered 
that pregnant dams that lost weight after PolyI:C administra-
tion had the highest serum TNF-α levels, and the offspring 
displayed the most severe behavioral deficits. On the other 
hand, the offspring of dams that gained weight and showed 
a minor rise in TNF-α after PolyI:C showed a more blunted 
phenotype. This may account for some variability in reporting 
certain behavioral deficits in this model, and perhaps, it may 
even be a decisive factor for the penetrance of this risk factor 
in humans, given that the immune response of pregnant moth-
ers can vary. After PolyI:C injection in the mother, there is a 
rise in several proinflammatory cytokines and chemokines in 
the fetal brain.150–152 Microglia expresses the TLR3 to which 
PolyI:C binds, evoking an innate immune response in both 
rodents and humans, and besides being able to respond to 
PolyI:C, they are able to sense changes in cytokine levels.153 
It is known that microglia during fetal development are con-
trolling and guiding neural precursor cells and axonal and 
dendritic outgrowth by active phagocytosis.154,155 They may, 
therefore, not be ready for an immune challenge yet. The 
interesting part is that this early activation seems to perma-
nently change microglial phenotype throughout development, 
as highlighted by a study in which they showed that following 
PolyI:C prenatal challenge in regions relevant to schizo-
phrenia, cytokines follow a precise expression pattern from 
P0–P60 and that MIA with PolyI:C disrupts this program.156 
In this regard, IL6 seems to play a major role in the PolyI:C-
induced neurodevelopmental derangement.142,151 In the 
absence of IL-6 (IL-6 knockout mice), the phenotype will 
not develop despite PolyI:C injection.142 There are evidences 
that microglia cells persist in an activated phenotype in the 
adult PolyI:C animal.18,19,157,158 This is in line with in vivo PET 
scan studies conducted on schizophrenic patients using the 
binding of a ligand to the peripheral benzodiazepine receptor 
as a measure for neuroinflammation. Activated microglia 
increase the expression of the peripheral benzodiazepine 
receptor. Thus, the measure of the ligand binding in the brain 
can be used as an in vivo correlate for microglia activation.15,16 
As we reported earlier, anti-inflammatory treatment with 
minocycline has been proven efficacious in human studies, 
especially in improving cognitive and negative symptoms, 
which are the most resistant to present treatment.159,160 
Minocycline has been applied in some studies to PolyI:C 
animals with promising preclinical results. Our group tested 
it successfully in a chronic treatment regimen, whereupon we 
showed a restoration of the deficits in PPI accompanied by 
decreased mRNA levels of IL-1β and TNF-α in microglia 
cells freshly isolated from the hippocampi of PolyI:C rats. 
This was accompanied by a restored adult hippocampal neu-
rogenesis.19 Meyer et al148 also showed that PolyI:C animals 
have decreased hippocampal neurogenesis, but clozapine 
treatment did not ameliorate the decrease, while we proved 
that minocycline did while decreasing microglial proinflam-
matory cytokine production. Van den Eynde et al157 observed 
that PolyI:C offspring showed increased microglial density 
in the chronic stage of the model (P180), accompanied by 
hypolocomotion and social defeat. Minocycline intervention 
restored social defeat.
A final remark on this model regards its phenotypical simi-
larities to autism spectrum disorders. As reviewed by Brown103 
prenatal immune activation can also confer risk for developing 
autism spectrum disorders. In fact, some components of the 
negative and cognitive symptom scales are overlapping with 
aspects of the autism spectrum.103,161 Likewise, behavioral 
abnormalities in the MIA models, for instance, increased 
stereotyped behaviors (eg, grooming), increased anxiety, and 
social defeat, along with several cognitive dysfunctions and 
PPI deficits, are considered also as correlates of phenomena 
observed in autism.161,162 As we discussed earlier, microglial 
activation following MIA may participate in the aberrant 
formation of brain systems, and they are also a component of 
the adult aspect of the disease in schizophrenic patients. Given 
that autism and schizophrenia share an environmental risk 
factor and some symptoms, they may even have in common 
persistent microglial activation.163–165 Table 1 summarizes the 
major behavioral deficits found in this model of schizophrenia 
and the outcome of the various treatments.
Prenatal LPS
Since bacterial infections during pregnancy have also been 
linked to the development of schizophrenia in the offspring, 
some groups use LPS as a “primary hit” during the same time 
windows.104 LPS binds to TLR4 in immune cells, thereby 
inducing a systemic innate immune response similar to 
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PolyI:C in terms of proinflammatory cytokine release such as 
IL-1β, IL-6, and TNF-α, although lacking the interferon-like 
response typical of viral immune challenge.108 It is difficult to 
directly compare the PolyI:C- and the LPS-exposed offspring 
since the studies conducted vary significantly and are incon-
sistent in the time point, the dose, and the amount of PolyI:C 
and LPS injections. Meyer107 recently compared in a direct 
way the general behavioral outcome of, among others, LPS 
and PolyI:C MIA models, and we refer to this review for a 
direct LPS vs PolyI:C comparison. As we will discuss, the 
phenotype of the adult offspring of dams challenged with 
LPS (also referred to as LPS animals) will present many 
similarities with the PolyI:C offspring, with several features 
matching a schizophrenic endophenotype.
Baharnoori et al166 and Santana et al167 demonstrated that 
LPS offspring display decreased D
2
 receptor binding potential 
in PV-positive GABAergic interneurons in the PFC. This is 
comparable to the lack of maturation in D
2
 receptor-mediated 
control of the GABAergic interneuron system in the PFC 
found in the nVHL model.73,75 Moreover, these findings are 
conformant with what Meyer107 found in the PolyI:C model. 
Baharnoori et al166 also showed altered DA transporter  bind-
ing in limbic regions, a sign of dopaminergic malfunction. 
Further evidence of anomalies in the DAergic system in 
this model comes from Borrell et al168 who found increased 
tyrosine hydroxylase immunoreactivity in the NcA of these 
animals, along with the findings of increased DA levels in 
the NcA and increased dihydroxyphenylacetic acid in the 
striatum by Romero et al.169 In this study, the authors also 
report increased immunoreactivity for synaptophysin in the 
frontal cortex and hippocampus, a clear sign of synaptic 
reorganization in these two areas in adult offspring from 
LPS challenged dams.169 Further cytoarchitectural abnor-
malities are found in the pyramidal neurons in the mPFC 
and CA1 region of the hippocampus.170 Dendritic arbor was 
found significantly decreased in both the regions, at differ-
ent postnatal time points, including adulthood, and as we 
mentioned earlier, dendritic spine pathology is a recognized 
feature in schizophrenic patients.170 Golan et al171 reported an 
increase in hippocampal pyramidal and granular cells with a 
shrinkage in cellular size, restricted to the pyramidal cells, 
further highlighting the sensitivity of the hippocampus to 
prenatal inflammatory insult. This model also presents with 
aberrations in the GABAergic system as it is the case in 
schizophrenic patients, the nVHL and the PolyI:C models. 
Basta-Kaim et al172 recently showed diminished total number 
of PV- and GAD67-positive neurons in the mPFC of adult 
LPS female animals, while the same changes occurred in 
the hippocampus of the males, although a decrease in PV-
positive axon terminals of GABAergic cells was reported in 
the mPFC of both sexes. On the other hand, Wischhof et al173 
showed a decrease in PV-positive neurons in the mPFC, 
hippocampus, and entorhinal cortex in both adult male and 
female LPS animals. The difference between the two studies 
may be due to the fact that Basta-Kaim et al172 administered 
LPS every second day, starting from G9 until delivery, 
whereas Wischhof et al173 administered two injections at 
G15 and G16. Furthermore, Li et al,139 Wischhof et al,173 
and Alvarado-Alanis et al138 also show impaired myelination 
in cortical and limbic regions in these mice, reflecting the 
abnormalities previously reported in the Poly:IC model and 
in schizophrenic patients.
LPS mice also display several schizophrenia end-
ophenotype-related behaviors which show up in early 
adulthood. Adult LPS mice show negative-like symptoms 
in the form of increased sensitivity to stress and increased 
despair in the forced swimming test, and also decreased 
social behavior and increased anxiety in the elevated plus 
maze test (Table 1).174–177 Wischhof et al173 demonstrated 
the presence of cognitive deficits in the form of impaired 
object recognition memory and also PPI deficits. Impaired 
spatial learning in the Morris’s water maze was also shown 
by Chlodzinska et al.178 Moreover, besides the PPI deficits, 
another sign of positive symptoms found in the LPS rodent 
model is the psychostimulant-induced hyperlocomotion, as 
shown by Basta-Kaim et al179 in a study in which they also 
demonstrate a hyperactive hypothalamic–pituitary–adrenal 
axis, which might be the reason for the altered stress respon-
siveness observed in this model by Lin et al.180 When it comes 
to the predictive validity of this model, only one study has 
shown that haloperidol treatment reverts the deficit in PPI, 
as did clozapine but not chlorpromazine, which decreased 
the amphetamine-induced hyperlocomotion, however.169,181 
The LPS model of schizophrenia has till date not been thor-
oughly investigated in terms of inflammatory processes and 
microglial activation. We could find two studies addressing 
this topic, both carried out by Graciarena et al.182,183 These 
studies showed that prenatal LPS leads to activated micro-
glia cells in the hippocampus of adult offspring, and this is 
accompanied by a decrease in transforming growth factor 
beta 1, lower adult hippocampal neurogenesis (in line with 
what we reported in the PolyI:C model), and deficits in the 
novel object recognition test.182–184 Furthermore, Cunningham 
et al155 demonstrated that microglia cells from the embryonic 
day 15 onward play a fundamental role in regulating the 
number of neuronal precursor cell (NPC) pool that are meant 
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to build the cerebral cortex by active phagocytosis of the 
NPCs. LPS challenge in pregnant dams between G15 and 
G16 can significantly decrease the number of neural precur-
sor cells possibly due to a significantly increased proportion 
of inducible nitric oxide synthase-positive microglia cells in 
the subventricular zone. These effects were ablated by anti-
inflammatory treatment with doxycycline, a tetracycline, and 
a close derivative of minocycline.155 This particular function 
of microglia has been shown to be important also in the adult 
regulation of neurogenesis in the hippocampus. Therefore, 
it is not surprising to find decreased neurogenesis in the adult 
offspring of PolyI:C- and LPS-treated dams, and also that 
treatment with minocycline improves neurogenesis, as we 
demonstrated.184–186 For an overview of the major behavioral 
deficits found in this model of schizophrenia and the outcome 
of the various treatments we refer to Table 1.
Conclusion
Overall, the construct validity of the MIA models with LPS 
and PolyI:C show great reliability, being based on human epi-
demiological observations. Moreover, there is no manipula-
tion in terms of lesions, administration of psychotropic drugs, 
or knockout/in of genes. On the contrary, they show a natural 
postpubertal outbreak of symptoms as observed in humans, 
suggestive of a neurodevelopmental course. As reviewed by 
Meyer,107 the PolyI:C model seems to have the widest array 
of schizophrenia-like behavioral aberrations. Moreover, 
as far as we could find in the literature, it has been more 
thoroughly characterized as compared to the LPS model. 
As for the face validity, both MIA models show structural, 
neurochemical, and behavioral abnormalities, which share 
a lot of common hallmarks with the human clinical picture. 
A growing body of evidence is associating schizophrenia to 
microglial activation and inflammation, with promising out-
come of anti-inflammatory intervention. The studies carried 
out so far in the PolyI:C model show that microglia activation 
is also a feature of this model, with the neurodevelopmental 
component and a proven efficacy of minocycline at least in 
the aspects screened up to date. One major limitation of this 
model is the fact that full organogenesis, including the brain, 
is completed after birth, while in humans it occurs in utero, 
and it is difficult to match the right trimester of rodents and 
humans.32 To our knowledge, the best way of getting around 
this issue has been proposed by Ratnayake et al32 by utilizing 
the spiny mouse strain, which has a complete organogenesis 
at birth with a gestational term of 39 days. The outcome of 
maternal PolyI:C exposure seems to be quite the same as 
for the other mice strain utilized for the purpose, including 
microglia cell reactivity. Nevertheless, as we mentioned 
earlier, some groups prefer to inject PolyI:C in early post-
natal days (P2–P6) to specifically target the corresponding 
early second trimester of pregnancy in humans.186 This is 
normally done in mouse strains that do not reach complete 
organogenesis at birth. As adults, the treated mice will display 
behavioral and neurochemical changes similar to those of the 
prenatally challenged animals, and it is therefore a model 
worth deeper characterization.186 However, these mice are 
directly exposed to PolyI:C and therefore lack the interface 
between MIA, placental and amniotic fluid alterations in 
cytokine expression, and, consequently, fetal brain changes 
in cytokine production that characterize the risk factor 
per se.187,188 A schizophrenic phenotype is most probably the 
result of susceptibility genes and environmental factors that 
disturb normal brain development and wiring.189 Therefore, 
studying this interaction would probably be a very good way 
of completing our understanding of this pathology and also 
for the development of novel pharmaceutical targets, eg, 
targeting more specifically microglia activation. Accordingly, 
in recent times, several groups started to combine the known 
etiological factors in animal models. One such example is the 
MIA with PolyI:C in DISC1 transgenic mice. Lipina et al190 
used a heterozygous mutant for a point mutation in the Disc1 
gene, which shows mild behavioral abnormalities reminis-
cent of schizophrenia and induced MIA at G9 with PolyI:C. 
The resultant adult offspring presented with intense deficits 
in social interaction, PPI, and LI, accompanied by reduced 
spatial object recognition, all stronger than those observed 
in the mutant mouse alone. Interestingly, the development 
of these phenotype could be blocked by coadministration 
of anti-IL-6 antibodies together with PolyI:C, highlighting 
the importance of inflammatory processes also in the gene–
environment interaction, as also shown by Lipina et al190 
and Smith et al142 in the PolyI:C model alone. DISC1 is also 
found in adult glia cells, although its function there is not 
yet known; this model provides a good tool to screen how 
these cells are affected by an aberrant DISC1 production. 
Other combinatorial strategies include the “two hit models”, 
where, eg, a first immunological hit (MIA) is combined 
with a peri- or a postpubertal second hit, usually involving 
physical or mental stress. This is based on the observation 
that the outbreak of schizophrenic symptoms often follows 
exposure to strong emotional stress that functions as a 
second hit in predisposed individuals primed earlier in life 
by either genes or an environmental factor. These studies 
reveal that the second hit with stress enhances the outbreak 
of schizophrenia-like symptoms in terms of stress responses, 
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neurochemical and behavioral changes.191–193 These are initial 
promising studies that pave the way for future research into 
following models that reproduces more than one etiological 
factor of schizophrenia, and they may represent the future tool 
to explore this pathology more in depth. Moreover, animal 
models will provide us with defined representations of single 
or multiple symptoms or hallmarks of a given disease. Thus, 
in the future, we might rather use a combination of different 
models to mimic a human pathology like schizophrenia in 
its complexity.
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